8-K filing — ADIAL PHARMACEUTICALS, INC. (ADIL)
Filed: 2026-10-16 AccNo: 0001213900-26-110349 Size: 193 KB Item 8.01: Other Events
Filings · News reference
Adial Pharmaceuticals Files Prospectus Related To The Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adial Pharmaceuticals granted 155,446 stock options to a new employee at an exercise price of $4.22 per share as an inducement to employment. The options vest over four years and have a ten-year term. The grant was made under Nasdaq Listing Rule 5635(c)(4). Following its June 2026 acquisition of Azora Therapeutics, Adial has shifted focus to treating inflammatory diseases, with AT177 as its lead program for ulcerative colitis treatment, currently in IND-enabling studies with an IND filing planned for H1 2027.
Adial Pharmaceuticals shares are trading lower after the company reported a wider net loss for the second quarter.